Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib in Advanced Hepatocellular Carcinoma
NCT02229071Phase 2Completed
- Sponsor
- Zelgen
- Start
- Apr 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Zelgen. Started Apr 2014; status: completed.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02229071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02229071.